A detailed history of Cadian Capital Management, LP transactions in Mirum Pharmaceuticals, Inc. stock. As of the latest transaction made, Cadian Capital Management, LP holds 475,714 shares of MIRM stock, worth $19.7 Million. This represents 0.95% of its overall portfolio holdings.

Number of Shares
475,714
Previous 1,235,121 61.48%
Holding current value
$19.7 Million
Previous $42.2 Million 56.07%
% of portfolio
0.95%
Previous 2.1%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$33.68 - $44.74 $25.6 Million - $34 Million
-759,407 Reduced 61.48%
475,714 $18.6 Million
Q2 2024

Aug 14, 2024

SELL
$23.57 - $34.85 $24.9 Million - $36.9 Million
-1,057,446 Reduced 46.12%
1,235,121 $42.2 Million
Q1 2024

May 15, 2024

BUY
$24.92 - $30.02 $8.91 Million - $10.7 Million
357,645 Added 18.48%
2,292,567 $57.6 Million
Q4 2023

Feb 14, 2024

BUY
$27.14 - $34.93 $13.6 Million - $17.5 Million
500,000 Added 34.85%
1,934,922 $57.1 Million
Q3 2023

Nov 14, 2023

BUY
$24.63 - $32.85 $4.19 Million - $5.58 Million
170,000 Added 13.44%
1,434,922 $45.3 Million
Q2 2023

Aug 14, 2023

BUY
$23.51 - $30.09 $12.5 Million - $15.9 Million
530,000 Added 72.12%
1,264,922 $32.7 Million
Q1 2023

May 15, 2023

BUY
$19.19 - $24.1 $6.86 Million - $8.62 Million
357,548 Added 94.75%
734,922 $17.7 Million
Q4 2022

Feb 13, 2023

SELL
$17.59 - $23.83 $17.4 Million - $23.5 Million
-987,412 Reduced 72.35%
377,374 $7.36 Million
Q3 2022

Nov 14, 2022

SELL
$19.98 - $29.44 $423,795 - $624,451
-21,211 Reduced 1.53%
1,364,786 $28.7 Million
Q2 2022

Aug 15, 2022

BUY
$18.42 - $27.5 $11.8 Million - $17.6 Million
640,997 Added 86.04%
1,385,997 $27 Million
Q1 2022

May 16, 2022

BUY
$15.5 - $23.93 $11.5 Million - $17.8 Million
745,000 New
745,000 $16.4 Million

Others Institutions Holding MIRM

About Mirum Pharmaceuticals, Inc.


  • Ticker MIRM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,751,700
  • Market Cap $1.53B
  • Description
  • Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the trea...
More about MIRM
Track This Portfolio

Track Cadian Capital Management, LP Portfolio

Follow Cadian Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cadian Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Cadian Capital Management, LP with notifications on news.